Hannah Furby1, Suzanne Moore2, Anna-Lena Nordstroem2, Richard Houghton2, Dimitra Lambrelli3, Sophie Graham3, Per Svenningsson4, Åsa Petersén5. 1. Roche Products Ltd, Welwyn Garden City, UK. hannah.furby@roche.com. 2. F. Hoffmann-La Roche Ltd, Basel, Switzerland. 3. Evidera, London, UK. 4. Section of Neurology, Karolinska University Hospital, Stockholm, Sweden. 5. Translational Neuroendocrine Research Unit, Department of Experimental Medical Science, Medical Faculty, Lund University, Lund, Sweden.
Abstract
BACKGROUND: Huntington's disease (HD) is a rare, neurodegenerative disease and its complex motor, cognitive and psychiatric symptoms exert a lifelong clinical burden on both patients and their families. OBJECTIVE: To describe the clinical burden and natural history of HD. METHODS: This longitudinal cohort study used data from the linked Swedish national registries to describe the occurrence of comorbidities (acute and chronic), symptomatic treatments and mortality in an incident cohort of individuals who either received the first diagnosis of HD above (adult onset HD; AoHD) or below (juvenile-onset HD; JoHD) 20 years of age, compared with a matched cohort without HD from the general population. Disease burden of all individuals alive in Sweden was described during a single calendar year (2018), including the occurrence of key symptoms, treatments and hospitalizations. RESULTS: The prevalence of HD in 2018 was approximately 10.2 per 100,000. Of 1492 individuals with a diagnosis of HD during 2002 and 2018, 1447 had AoHD and 45 had JoHD. Individuals with AoHD suffered a higher incidence of obsessive-compulsive disorder, acute psychotic episodes, pneumonia, constipation and fractures compared with matched controls. Individuals with JoHD had higher incidence rates of epilepsy, constipation and acute respiratory symptoms. Median time to all-cause mortality in AoHD was 12.1 years from diagnosis. Patients alive with HD in Sweden in 2018 displayed a pattern of increased clinical burden for a number of years since diagnosis. CONCLUSIONS: This study demonstrates the significant and progressive clinical burden in individuals with HD and presents novel insights into the natural history of JoHD.
BACKGROUND: Huntington's disease (HD) is a rare, neurodegenerative disease and its complex motor, cognitive and psychiatric symptoms exert a lifelong clinical burden on both patients and their families. OBJECTIVE: To describe the clinical burden and natural history of HD. METHODS: This longitudinal cohort study used data from the linked Swedish national registries to describe the occurrence of comorbidities (acute and chronic), symptomatic treatments and mortality in an incident cohort of individuals who either received the first diagnosis of HD above (adult onset HD; AoHD) or below (juvenile-onset HD; JoHD) 20 years of age, compared with a matched cohort without HD from the general population. Disease burden of all individuals alive in Sweden was described during a single calendar year (2018), including the occurrence of key symptoms, treatments and hospitalizations. RESULTS: The prevalence of HD in 2018 was approximately 10.2 per 100,000. Of 1492 individuals with a diagnosis of HD during 2002 and 2018, 1447 had AoHD and 45 had JoHD. Individuals with AoHD suffered a higher incidence of obsessive-compulsive disorder, acute psychotic episodes, pneumonia, constipation and fractures compared with matched controls. Individuals with JoHD had higher incidence rates of epilepsy, constipation and acute respiratory symptoms. Median time to all-cause mortality in AoHD was 12.1 years from diagnosis. Patients alive with HD in Sweden in 2018 displayed a pattern of increased clinical burden for a number of years since diagnosis. CONCLUSIONS: This study demonstrates the significant and progressive clinical burden in individuals with HD and presents novel insights into the natural history of JoHD.
Authors: Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi Journal: Nat Rev Neurol Date: 2014-03-11 Impact factor: 42.937
Authors: Gillian P Bates; Ray Dorsey; James F Gusella; Michael R Hayden; Chris Kay; Blair R Leavitt; Martha Nance; Christopher A Ross; Rachael I Scahill; Ronald Wetzel; Edward J Wild; Sarah J Tabrizi Journal: Nat Rev Dis Primers Date: 2015-04-23 Impact factor: 52.329
Authors: Leslie J Cloud; Adam Rosenblatt; Russel L Margolis; Christopher A Ross; Jagan A Pillai; Jody Corey-Bloom; Hannah M Tully; Thomas Bird; Peter K Panegyres; Charles A Nichter; Donald S Higgins; Sandra L Helmers; Stewart A Factor; Randi Jones; Claudia M Testa Journal: Mov Disord Date: 2012-11-02 Impact factor: 10.338
Authors: Michael D Rawlins; Nancy S Wexler; Alice R Wexler; Sarah J Tabrizi; Ian Douglas; Stephen J W Evans; Liam Smeeth Journal: Neuroepidemiology Date: 2016-01-30 Impact factor: 3.282
Authors: Stephen J W Evans; Ian Douglas; Michael D Rawlins; Nancy S Wexler; Sarah J Tabrizi; Liam Smeeth Journal: J Neurol Neurosurg Psychiatry Date: 2013-03-12 Impact factor: 10.154